Edwards puts more focus on heart valves after $140m LifeStent sale to Bard
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences has agreed to sell its LifeStent peripheral vascular product line to CR Bard for $140m. Edwards will receive an initial cash payment of $75m, plus $65m cash upon the achievement of certain milestones, including US regulatory approval of another indication for the product.